MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Revvity Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

103.65 -0.9

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

102.7

Max

106.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-8.6M

47M

Pardavimai

-21M

699M

P/E

Sektoriaus vid.

52.608

87.826

Pelnas, tenkantis vienai akcijai

0.4

Dividendų pajamingumas

0.29

Pelno marža

6.675

Darbuotojai

11,000

EBITDA

-14M

181M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+11.47% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.29%

2.26%

Kitas uždarbis

2026-01-30

Kitas dividendų mokėjimo data

2026-02-06

Kita Ex Dividend data

2026-01-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

569M

12B

Ankstesnė atidarymo kaina

104.55

Ankstesnė uždarymo kaina

103.65

Naujienos nuotaikos

By Acuity

29%

71%

87 / 370 reitingas Healthcare

Revvity Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-12 23:54; UTC

Rinkos pokalbiai

CBA Could Underperform Again in 2026 -- Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Weaker Yen -- Market Talk

2026-01-12 23:43; UTC

Rinkos pokalbiai

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026-01-12 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026-01-12 21:56; UTC

Rinkos pokalbiai

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-12 21:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 21:18; UTC

Rinkos pokalbiai

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026-01-12 20:54; UTC

Uždarbis

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026-01-12 20:48; UTC

Rinkos pokalbiai

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026-01-12 20:33; UTC

Rinkos pokalbiai

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026-01-12 20:18; UTC

Įsigijimai, susijungimai, perėmimai

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026-01-12 19:39; UTC

Rinkos pokalbiai

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026-01-12 19:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-01-12 19:33; UTC

Rinkos pokalbiai

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026-01-12 19:24; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026-01-12 19:22; UTC

Įsigijimai, susijungimai, perėmimai

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026-01-12 18:21; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026-01-12 18:20; UTC

Įsigijimai, susijungimai, perėmimai

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026-01-12 18:19; UTC

Rinkos pokalbiai

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026-01-12 18:16; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-12 18:09; UTC

Rinkos pokalbiai

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026-01-12 18:01; UTC

Įsigijimai, susijungimai, perėmimai

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026-01-12 18:00; UTC

Rinkos pokalbiai

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Akcijų palyginimas

Kainos pokytis

Revvity Inc Prognozė

Kainos tikslas

By TipRanks

11.47% į viršų

12 mėnesių prognozė

Vidutinis 113.38 USD  11.47%

Aukščiausias 123 USD

Žemiausias 105 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Revvity Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

10 ratings

6

Pirkti

4

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

87 / 370 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat